d 61519 proteomics · research article an organelle proteomic method to study...
TRANSCRIPT
PROTEOMICSD 61519
REPRINT
PR
OT
EO
MIC
S · Vo
l.7 (2007) No
.18 · Pag
es 3431–3636
www.proteomics-journal.com
TechnologyBioinformaticsProtein ArraysMicrobiologyPlant ProteomicsAnimal Proteomics
34352_Titel_Proteomics_Reprint 21.09.2007 10:54 Uhr Seite 1
RESEARCH ARTICLE
An organelle proteomic method to studyneurotransmission-related proteins, applied to aneurodevelopmental model of schizophrenia
Freya G. G. Vercauteren1, 2, Gonzalo Flores1, 3, Weiya Ma1, Jean-Guy Chabot1,Lieve Geenen2, Stefan Clerens2, Ali Fazel4, John J. M. Bergeron4, Lalit K. Srivastava1,Lutgarde Arckens2 and R�mi Quirion1
1 Department of Psychiatry, Douglas Mental Health University Institute, McGill University,Montr�al, Qu�bec, Canada
2 Laboratory of Neuroplasticity and Neuroproteomics, Katholieke Universiteit Leuven, Leuven, Belgium3 Laboratorio de Neuropsiquiatria, Instituto de Fisiologia, Universidad Autonoma de Puebla, Puebla, Mexico4 R�seau Prot�omique de Montr�al-Montreal Proteomics Network (RPMPN), McGill University,
Montr�al, Qu�bec, Canada
Limited information is currently available on molecular events that underlie schizophrenia-likebehaviors in animal models. Accordingly, we developed an organelle proteomic approach enablingthe study of neurotransmission-related proteins in the prefrontal cortex (PFC) of postpubertal(postnatal day 60 (PD60)) neonatally ventral hippocampal (nVH) lesioned rats, an extensively usedneurodevelopmental model of schizophrenia-like behaviors. The PFC was chosen because of itspurported role in the etiology of the disease. Statistical analysis of 392 reproducible spots on 2-Dorganelle proteomic patterns revealed significant changes in intensity of 18 proteinous spots inplasma membrane-enriched fractions obtained from postpubertal nVH lesioned rats compared tocontrols. Mass spectrometric analysis and database searching allowed the identification of a singleprotein in each of the nine differential spots, including proteins of low abundance, such as neuro-calcin d. Most of the identified dysregulated proteins, including clathrin light chain B, syntaxinbinding protein 1b and visinin-like protein 1 are known to be linked to various neurotransmittersystems and to play key roles in plasma membrane receptor expression and recycling as well assynaptic vesicle exocytosis/recycling. Organelle proteomic approaches have hence proved to bemost useful to identify key proteins linked to a given behavior in animal models of brain diseases.
Received: April 14, 2007Revised: June 12, 2007
Accepted: June 13, 2007
Keywords:2-D electrophoresis / Animal model / Organelle / Plasma membrane / Schizophrenia
Proteomics 2007, 7, 3569–3579 3569
1 Introduction
Schizophrenia is a chronic mental illness affecting about 1%of the adult world population. Symptoms of schizophreniatypically occur after puberty and include positive (psychosis,hallucinations, and delusional ideas) and negative (apathy,alogia, and social withdrawal) symptoms [1], as well as cog-nitive impairments associated with frontal lobe dysfunc-tions. Some of these symptoms are treated with neuroleptics,targeting mainly dopaminergic, and serotonergic neuro-transmission [2, 3].
Genetic studies have recently revealed a series of suscep-tibility genes linked to schizophrenia [4], most of which
Correspondence: Dr. R�mi Quirion, Douglas Mental Health Uni-versity Institute, McGill University, Institute of Neuroscience,Mental Health and Addiction, 6875 LaSalle Boulevard, Montr�al,QC, Canada, H4H 1R3E-mail: [email protected]: 11-514-762-3034
Abbreviations: ACh, acetylcholine; ASB-14, amidosulfobetaine-14; CKB, creatine kinase B; DTE, dithioerythritol; mAChR, mus-carinic acetylcholine receptor; nVH, neonatal ventral hippocam-pal; PD60, postnatal day 60; PEBP, phosphatidyl ethanolaminebinding protein; PFC, prefrontal cortex; SNARE, soluble N-ethyl-amide sensitive factor attachment receptor; STXb, syntaxin bind-ing protein
DOI 10.1002/pmic.200700379
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
3570 F. G. G. Vercauteren et al. Proteomics 2007, 7, 3569–3579
encode neurotransmission-related proteins, including cate-chol O-methyltransferase (COMT) [5], metabotropic gluta-mate receptor 3 (mGluR3) [6], glutamate decarboxylase 1 [7],reelin [8], neuregulin 1 (NRG1) [9], and regulator of G-pro-tein signaling 4 (RGS4) [10]. In addition, supporting the hy-pothesis that schizophrenia is a neurodevelopmental dis-order, multiple schizophrenia susceptibility loci are asso-ciated with proteins involved in neuronal development,including disrupted-in-schizophrenia 1 (DISC-1) [11], NRG1[9, 12], and dysbindin-1 [13]. The altered expression of anumber of neurotransmission-related proteins has also beenshown in brain tissues obtained from schizophrenic patientsand relevant animal models (e.g., synaptosomal-associatedprotein 25 (SNAP-25) [14], N-methyl-D-aspartic acid (NMDA)receptor subunit NR2B and postsynaptic density protein 95[15]).
However, mechanisms possibly underlying schizo-phrenia phenotypes and these neurotransmission-relatedsusceptibility genes are still unclear. Moreover, no diagnosticor molecular markers for schizophrenia-related behaviorsare currently available and in contrast to diseases such asAlzheimer’s disease, no clear neuropathological featurescharacterize schizophrenia [4]. The discovery of reliable bio-markers could facilitate diagnosis and treatment of this dis-order and foster research on its etiology.
Besides genetically predisposed neuronal vulnerability,stressful life events including early neurodevelopmentalabnormalities that can affect neuronal migration, survival,and connectivity are most likely involved in the etiology ofschizophrenia [16–18]. Accordingly, a neurodevelopmentalmodel that has been extensively used to study schizo-phrenia-like behaviors is the neonatal ventral hippocampal(nVH) lesioned rat. In this model, excitotoxic lesions areperformed in the ventral hippocampus of rat pups at post-natal day 7 (PD7 [19, 20]). These nVH lesions alter hippo-campal inputs to target structures such as the prefrontalcortex (PFC) and disrupt the normal development of thelatter [19]. Interestingly, molecular, behavioral, and anato-mical features of postpubertal (PD60 and older) but notprepubertal nVH lesioned rats mimic several features ofschizophrenia [19, 21–25]. Although these alterations couldat least partially be due to the absence of the ventral hip-pocampus, these changes may reflect schizophrenia-likeprefrontal dysfunction in this animal model. These schi-zophrenia-like behaviors include deficits in prepulse inhi-bition of startle and social interactions [26], impairments inworking memory [27], hyperresponsiveness to dopamineagonists [19, 23], reduced glutamatergic neurotransmission[28], and molecular [23, 24, 29] and morphological [30]alterations similar to some seen in schizophrenic patients.
In addition to genomic microarray studies [31, 32], prote-omic approaches have proven to be particularly useful forscreening molecular changes in healthy and diseased tissues[33–35] and for studying the expression profile of hundreds ofproteins and their isoforms under a given condition. In addi-tion, organelle fractionation of the tissue sample preceding
proteomic analysis substantially decreases the complexity ofprotein extracts and thus increases the likelihood of identify-ing less abundant proteins [36–39]. However, because of theunique physical properties of proteins present in each organ-elle fraction, the 2-DE separation of each of these groups ofproteins requires specific solubilization methods and experi-mental conditions in order to obtain highly reproducible pro-teomic patterns for quantitative comparative analysis. Forexample, plasma membrane proteins are highly hydrophobicand, therefore, tend to precipitate during IEF, rendering theirquantitative analysis via 2-DE proteomic approaches ratherchallenging [40, 41]. In addition to difficulties in solubiliza-tion of plasma membrane- and vesicle-associated proteins,lipid contents also limit the compatibility of the proteinextracts with 2-DE analysis [42]. This is particularly relevant inbrain tissues well known to be enriched in lipids.
In the present study, an organelle purification methodcombined with 2-DE was developed and used to investigatedifferential protein expression in the postpubertal lesionednVH rat model of schizophrenia. Since frontal lobe dys-function is a hallmark of schizophrenia, the PFC was cho-sen for our experimental analysis, as a key region involvedin the disease process. In order to increase the compat-ibility of plasma membrane- and vesicle-associated proteinswith 2-DE analysis, we first optimized 2-DE-separation ofproteins in plasma membrane- and vesicle-enriched frac-tions of brain tissue, testing different combinations ofchaotropes and detergents to improve the solubility ofproteins in various organelle fractions. Our data show thatvarious neurotransmission-related proteins at the level ofthe plasma membrane and synaptic vesicles are differen-tially expressed in the PFC of postpubertal nVH lesionedrats compared to sham operated rats. Although certainreceptors and other proteins have been reported to be dif-ferentially modulated in the nVH lesioned model and/orschizophrenic patients [5–15], the underlying molecularmechanisms are still unknown. The proteins identified inthe present study may help provide a more detailed overallpicture of changes occurring in exocytosis and/or endocy-tosis of these systems.
2 Materials and methods
2.1 Chemicals
Most chemicals were purchased from Sigma–Aldrich (Oak-ville, ON, Canada) (ibotenic acid, glycerol, Brilliant blue G,CHAPS, agarose, EDTA), Roche Diagnostics (Laval, QC,Canada) (TRIS base, glycine), BioRad (Laval, QC, Canada)(acrylamide, bis-acrylamide), and EMD Biosciences (Mis-sissauga, ON, Canada) (amidosulfobetaine-14 (ASB-14)).Complete Protease Inhibitor tablets and SDS were obtainedfrom Boehringer Mannheim (Laval, QC, Canada) and PierceBCA Protein Assay kit from Pierce Chemical (Rockford, IL,USA). Sequencing grade modified porcine trypsin was pur-
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2007, 7, 3569–3579 Animal Proteomics 3571
chased from Promega (Leiden, The Netherlands). HPLC-grade water was obtained from Acros Organics (Geel, Bel-gium); ACN was purchased from Biosolve (Valkenswaard,The Netherlands); TFA from Beckman (Fullerton, CA, USA)and formic acid from Riedel-de Ha�n (Seelze, Germany).Qualitative and quantitative analysis of 2-DE proteomic pat-terns were performed using ProFinder software (PerkinElmer, Boston, MA, USA).
2.2 Neonatal ventral hippocampal lesions (nVH)
nVH lesioned rats were generated as described previously[20]. Briefly, pregnant Sprague-Dawley rats at gestationaldays 14–17 were obtained from Charles River Canada (St-Constant, Quebec, Canada) and housed individually in12 h light/dark cycle rooms and fed ad libitum. Animalcare and surgeries were performed according to the guide-lines approved by the McGill University Animal CareCommittee and the Canadian Council for Animal Care. Onpostnatal day 7 (PD7), male pups within each litter wererandomly assigned sham or nVH lesion status. Pups wereanaesthetized by hypothermia by placing them on ice for20 min and were then laid on a platform fixed to a stereo-taxic instrument. At coordinates anteroposterior –3.0 mm,mediolateral 63.5 mm relative to bregma and dorsoventral–4.9 mm relative to the dura [20], a cannula connected toan infusion pump through a Hamilton syringe was insert-ed into each ventral hippocampus. Ibotenic acid (0.3 mL,10 mg/mL) in 0.15 M PBS pH 7.4 was infused bilaterally.Sham operated animals received 0.3 mL of 0.15 M PBSpH 7.4. The needle was withdrawn 2 min after completionof the infusion. Pups recovered from the operation on aheated pad and were returned to their respective mothers.On PD21, rats were weaned and grouped three per cage.Experiments were performed on postpubertal (PD60) ani-mals.
2.3 Histology
In order to assess the extent of the ventral hippocampallesions and sham operations, nVH lesioned and sham ratswere decapitated at PD60 and brains were snap-frozen in 2-methylbutane at –407C. Coronal sections (20 mm) werestained with cresyl violet and location and size of the lesionswere examined under light microscopy.
2.4 Sample preparation
On PD60, PFC tissue was obtained from ten male nVHlesion rats and ten sham littermates. The PFC brain tissueused in the proteomic study included the following areas:frontal association, cingulate 1 and 2, orbital, agranularinsular, and dorsal peduncular cortices [43]. Random proteindegradation inevitably occurs during a lengthy tissue dissec-tion as well as during the subsequent organelle purificationperformed in this study, leading to changes on 2-DE prote-
omic patterns and possibly false-positive results. Therefore,we opted to dissect a slightly larger brain area, including tis-sue located frontally to the forceps minor of the corpus cal-losum. Accordingly, very small parts of the prelimbic, pri-mary somatosensory and primary motor cortices 1 and 2,frontal to the forceps minor, have also been included in thetissue used for organelle proteomic analysis. These areas areglobally referred to as PFC in the remaining of the manu-script.
In contrast, the brain areas used for the confirmation ofWestern blotting experiments included only the frontal as-sociation and cingulate cortices.
For each animal, brain tissue was mechanically ho-mogenized in ice-cold homogenization buffer (0.32 Msucrose, 5 mM Tris base pH 7.4, 1 mM EDTA, CompleteProtease Inhibitor). Protein extracts were enriched inplasma membrane- and vesicle-associated proteins bymeans of differential centrifugation at the followingspeeds: 480, 4400, 63 000, and 200 0006g. Plasma mem-brane enriched pellets were identified by means of Westernblotting using plasma membrane marker anti-ATPase a1
antibody (see Section 2.5) and subsequently centrifuged at107 0006g during 17 h on a 0.5–1.8 M continuous sucrosegradient. Enrichment of sucrose gradient fractions inplasma membranes was again analyzed by means ofWestern blotting using the anti-ATPase a1 antibody. Pro-tein concentration was determined by means of the PierceBCA Protein Assay kit and protein fractions were stored at–807C until further use.
2.5 Western blotting for sample preparation
Fractions obtained from differential centrifugation or fromsucrose gradient centrifugation were analyzed by Westernblotting. Equal amounts of protein samples were added toan appropriate amount of 66 SDS sample buffer(62.5 mM Tris-HCl, pH 6.8, 2% w/v SDS, 1% glycerol,50 mM DTT, and 0.1% w/v bromophenol blue), incubatedat 657C for 5 min, centrifuged at 13 500 rpm for 5 min andseparated on 4–20% polyacrylamide gels. The resolvedproteins were subsequently transferred to Hybond-C NC.Membranes were incubated with 5% nonfat milk in TBST(10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.2% Tween 20)for 2 h at room temperature and incubated with anti-ATPase a1 mAb (Abcam, Cambridge, MA). The mem-branes were then washed three times with TBST andincubated with HRP-conjugated antimouse secondary anti-body (Santa Cruz Biotechnology, Santa Cruz, CA) inTBST for 1 h at room temperature. After three washes withTBST, protein bands were visualized by means of theWestern Lightning kit (Perkin Elmer). Part of the SDSgel was stained with CBB to ensure the use of equalamounts of proteins. Pellets and sucrose gradient fractionsthat were highly enriched in plasma membranes comparedto other pellets and fractions were used for proteomicanalysis.
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
3572 F. G. G. Vercauteren et al. Proteomics 2007, 7, 3569–3579
2.6 2-DE and software analysis
Protein extracts were resuspended in 4% w/v CHAPS,40 mM dithioerythritol (DTE), 20 mM Tris-base, 0.5% bro-mophenol blue and 1% IPG buffer, combined with either7 M urea, 2 M thiourea (buffer A) or 9.8 M urea, 2 M thio-urea, and 2% ASB-14 (buffer B), and rehydrated for 15 h45 min on Immobiline� DryStrips (18 cm, NL, pH 3–10).After rehydration, proteins were focused on an IPGphorapparatus sequentially at 300, 700, 1000, 1500, 2000, 2500,and 3000 V. The IPG strips were then equilibrated twice for15 min in a solution containing 6 M urea, 20% SDS, 30%glycerol, and 1.5 M Tris-HCl at pH 8.8 with 2% w/v DTE,then with 2.5% w/v iodoacetamide. Subsequently, IPG stripswere placed on top of SDS-polyacrylamide gradient gels (7–15%). A broad range marker spanning the range 10–200 kDa(BioRad) was run alongside the samples. Gels were stainedwith SYPRO ruby and images were acquired using a Pro-Xpress scanner and ProScan software (Perkin Elmer). Imageanalysis was performed utilizing ProFinder software (PerkinElmer). Spot detection, spot matching, and normalizationperformed with the software were visually checked and dif-ferences in spot intensities (spot volume6OD) between bothgroups were statistically analyzed (Student t-test, n = 10,p,0.05, ProFinder).
2.7 Trypsin digestion
Differential gel spots were diced and washed for 15 min inHPLC-grade water. Following a series of washes of2615 min HPLC-grade water, 2615 min 50% v/v ACN, and265 min water, gel pieces were dried in a vacuum cen-trifuge, and were subsequently incubated overnight at 377Cin 40 mL 25 mM NH4HCO3 (pH 8.0) containing 5% v/v ACNand 0.1 mg of trypsin. Tryptic peptide digests were extractedby two consecutive washes of 30 min in a bath sonicator with5% v/v ACN, 0.1% formic acid, and 10% ACN in 0.1% formicacid in water. Extracts were concentrated to 30–50 mL in avacuum centrifuge and stored at –207C. Prior to MS, sampleswere desalted and concentrated using C18 ZipTips (Milli-pore, Bedford, MA, USA). Briefly, the C18 media was acti-vated by pipetting 4610 mL of 100% ACN, followed by4610 mL of 50% v/v ACN with 0.1% v/v TFA in water, andequilibrated with 0.1% v/v TFA in water. The peptide samplewas bound to the ZipTip and subsequently washed with4610 mL of 0.1% v/v TFA in water and 4610 mL of 0.1% v/vformic acid in water. ZipTip elution was done with 2.5 mL of50% v/v ACN and 1% formic acid in water.
2.8 Mass spectrometric analysis and proteinidentification
For MALDI PMF analysis, 0.8 mL of the sample was spottedon a MALDI target plate, together with 0.8 mL of matrix solu-tion (5 mg of CHCA dissolved in 500 mL of 50% ACN in 1%v/v formic acid). MALDI spectra were acquired on a MALDI-
TOF mass spectrometer (Reflex IV, Bruker Daltonics, Bre-men, Germany). Automated batch LC-MS analyses were runon an Ultimate nano-LC system (LC Packings, San Francisco,CA, USA) online coupled to a quadrupole-TOF (Q-TOF) massspectrometer (Micromass, Manchester, UK). Briefly, thesample was diluted to 12 mL using 5% v/v ACN, 0.1% v/vformic acid, and pipetted in the LC autosampler vial. 10 mL ofthis solution was loaded on the precolumn and RP eluted overthe capillary column at a flow rate of 150 nL/min, using agradient of 5–95% ACN in 45 min.
PMF peak lists were produced using MASCOT Wizardand sent to the MASCOT PMF server (www.ma-trixscience.com). Searching was conducted in both theNCBInr database and the Swiss-Prot database with tax-onomy restricted to rat. The searches were performed withthe following specifications: carbamidomethyl cysteine asfixed modification, oxidized methionine as variable mod-ifications, one missed cleavage site allowed, and a peptidetolerance of 0.3 Da. MS/MS spectra and LC-MS data weresent to the MASCOT MS/MS ions search engine using thesame parameters as for PMF searching, except for a peptidetolerance of 0.6 Da. In addition, an MS/MS tolerance of0.3 Da and the ESI-quadrupole-TOF (ESI-QUAD-TOF)instrument were specified.
2.9 Confirming Western blotting experiments
Differential protein expression levels observed in 2-DE anal-yses were confirmed by means of Western blotting onplasma membrane- and vesicles-enriched PFC fractionsobtained from nVH lesioned rats and sham littermates. Thefollowing antibodies were used: antisyntaxin b1 polyclonalantibody (Sigma, St-Louis, MO), antiphosphatidyl ethanol-amine-binding protein polyclonal antibody (Calbiochem,San Diego, CA), antineurocalcin d polyclonal antibody (Bio-Mol, Plymouth Meeting, PA, Canada), anti-ATPaseb mAb(Sigma), anticlathrin light chain b polyclonal antibody (SantaCruz Biotechnology, Santa Cruz, CA), antidihydrolipoyl-lysine S-acetyltransferase E2 polyclonal antibody (GenWay,San Diego, CA) and antivisinin-like protein1 polyclonal anti-body (Professor Dr. K.-H. Braunewell, Humboldt University,Berlin, Germany). Antimouse, antirabbit, and antichickensecondary antibodies were obtained from Santa Cruz Bio-technology. Western blotting experiments were performed asdescribed in Section 2.5.
3 Results
3.1 Optimization of 2-DE separation of organelleproteins
In order to improve analysis of plasma membrane- and vesi-cle-extracts obtained from lipid-rich brain tissue by means of2-DE protein separation, the comparative efficacy of differentchaotropes and detergents was investigated first. Different
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2007, 7, 3569–3579 Animal Proteomics 3573
mixtures and concentrations of urea, thiourea, CHAPS, andASB-14 were tested. Figure 1 shows that a given mixture ofurea, thiourea, CHAPS, and ASB-14 (buffer B) significantlyimproved the quality of 2-DE proteomic patterns of fractionsenriched in plasma membranes and vesicles. In particular, asignificant increase in resolution was obtained for proteinspots present in the basic part of the gel, as well as for pro-teins with low molecular weight. The finding that ASB-14improves the quality of 2-DE patterns for plasma membrane-enriched protein fractions from brain tissues is in agreementwith results obtained in other tissues and cell preparations[42, 44–46].
3.2 Analysis of experimental samples
The size and location of the lesions were verified in PD60nVH lesioned animals by means of cresyl violet staining andas shown in Fig. 2, significant bilateral damage of the ventralhippocampus including neuronal loss, atrophy, and cavita-tion was observed in these rats (Fig. 2A). Animals exhibitingdamage in the dorsal half of the hippocampus, thalamus, orcortex were excluded from the study. Sham-operated animals
did not show any obvious damage in any hippocampal area(Fig. 2B).
Protein fractions enriched in plasma membranes andvesicles obtained from the PFC of ten PD60 nVH lesionedrats and ten control littermates, were solubilized as de-scribed above and separated on 2-D gels (Fig. 3). Thus, eachgel contained an organelle proteomic pattern of a singleanimal. Approximately 1400 spots were detected on each ofthe 20 gels. Spot detection was visually confirmed. Spots instreaking areas as well as elliptical spots were discarded.Only spots present and well defined on all 20 gels weretaken into account for statistical analysis. Scatter plots ofintensities of this selection of 392 highly reproducible spotswere made for all proteomic patterns on gels from bothcontrol and experimental samples in order to test the be-tween-sample reproducibility level and to screen for out-liers. The location and intensity of each spot on the matchedspot patterns of nVH lesioned and control animals werequalitatively and quantitatively compared. Results of com-puter analyses were verified by visual examination and dif-ferences in spot intensities between both groups were sta-tistically analyzed.
Figure 1. 2-DE gel patterns ofprotein fractions extracted fromrat PFC enriched in plasmamembranes and vesicles, andrehydrated in 4% w/v CHAPS,40 mM DTE combined witheither (A) 9.8 M urea, 2 M thiou-rea, or (B) 7 M urea, 2 M thiou-rea, 2% ASB-14. Proteins wereseparated on pH 3–10 IPG-stripsand 7–15% gradient SDS-PAGEgels. Gels were stained withSYPRO ruby.
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
3574 F. G. G. Vercauteren et al. Proteomics 2007, 7, 3569–3579
Figure 2. Anatomical validation of nVH lesions. Coronal hemi-sections (bregma-4.80 [42]) of adult rat brains stained with cresylviolet demonstrate structural damages in the ventral hippo-campus of adult lesioned rats, resulting from the neonatal lesion(A), compared to sham-operated control rats (B). Scale bar: 2 mm.
Statistical analysis revealed that the intensity of 18 spotswas significantly different on the organelle proteomic pat-terns of nVH lesion animals versus controls (p,0.05, n = 10,Student t-test, ProFinder). Following mass spectrometricanalysis, nine spots unambiguously contained a single pro-tein as identified by NCBI and Swiss-Prot database searching(Table 1). Insufficient protein sample was available tounambiguously identify by MS the proteins present in theother nine differential spots. The location of the spots con-taining the identified proteins on the proteomic patterns isshown in Fig. 3. Seven of these spots were less intense fororganelle proteomic patterns obtained from nVH lesionedanimals, while two spots were more intense, compared todata obtained from control littermates (Table 1). Westernblotting experiments performed on PFC protein extractsenriched in plasma membranes and vesicles confirmed thesignificant changes in protein expression levels as observedin 2-DE analysis in postpubertal lesioned animals versussham animals (Fig. 4; the seven proteins for which an anti-body was available). The fold changes in intensity of the sig-nificantly different spots of the 2-DE patterns, as well as the
corresponding bands in Western blotting experiments areshown in Table 1 and Fig. 4. Table 1 and Fig. 5 indicate theintracellular distribution, as listed in the Swiss-Prot data-base, as well as functional categories of proteins identified asdifferentially altered in nVH lesioned animals. They includeproteins known to play major roles in synaptic vesicle exocy-tosis and recycling, such as syntaxin binding protein 1(STXb1) and clathrin light chain B (CLCB), as well as pro-teins involved in the modulation of signal transduction(phosphatidyl ethanolamine binding protein (PEBP), neuro-calcin d (ncald), visinin-like 1 (VILIP1), ATPase b). In addi-tion, expression levels of the fatty acid metabolism-relatedprotein dihydrolipoyllysine S-acetyltransferase E2 (DLAT), ofthe energy metabolism- and neuroprotection-related protein,creatine kinase B (CKB), as well as of hypothetical proteinmKIAA1045, were found to be altered in the PFC of post-pubertal nVH lesioned rats.
4 Discussion
In the present organelle proteomic analysis, significant mo-lecular alterations were identified in the PFC of PD60 nVHlesioned rats, an animal model of schizophrenia-like behav-iors. Using a specific mixture of urea, thiourea, CHAPS andASB-14 (buffer B), the applied 3-D proteomic approachenabled us to focus our study on neurotransmission-relatedproteins at the level of the plasma membrane and synapticvesicles. The applied protein solubilization method yieldedhighly reproducible 2-DE organelle proteomic patterns, withsignificantly increased resolution of protein spots for bothbasic proteins and small proteins. This method also allowedfor quantitative comparison of protein expression in frac-tions obtained from PD60 nVH lesioned and sham-operatedanimals. Compared to whole-cell proteomic approaches, theorganelle proteomic method used here reduces interferencefrom highly abundant proteins expressed in various cellfractions, allowing for the study of less abundant proteins,including neurocalcin d, visinin-like 1 and PEBP.
Using this improved method, seven proteins wereobserved to be down-regulated, while two were increased inplasma membrane- and vesicle-enriched fractions of the PFCof PD60 nVH lesioned rats compared to littermate controls.The observed changes are likely due to altered expressionand/or redistribution into different cellular compartments.Further studies are now underway to establish the mostlikely hypothesis.
Most of the identified dysregulated proteins are known toplay various roles in plasma membrane receptor expressionand recycling, as well as in synaptic vesicle exocytosis orrecycling. These results are in accordance with earlier datademonstrating that various neurotransmitter systems arealtered in the PFC of postnatally nVH lesioned rats, leadingto schizophrenia-like behaviors [23, 24, 28, 29], and may fur-ther complete the overall picture of altered protein expres-sion under these conditions.
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2007, 7, 3569–3579 Animal Proteomics 3575
Figure 3. Location of differentialspots as observed in a typicalPD60 nVH lesioned animal 2-Dprotein pattern (IPG pH 3–10; 7–15% SDS-PAGE), visualized withSYPRO ruby staining. Only well-defined spots present on all 20gels were taken into account forstatistical analysis. SSP-num-bers of the differential spots(ProFinder software analysis)are indicated.
4.1 Proteins involved in neurotransmitter release
One of the down-regulated proteins observed in this study isSTXb1. STXb1 binds and inhibits syntaxins of the soluble N-ethylamide sensitive factor attachment receptor (SNARE)complex [47–49]. It functions in intracellular membranefusion processes, facilitating vesicle docking [50, 51] andhence, neurotransmitter release. The down regulation ofSTXb1 as observed here, could therefore contribute toincreased release of neurotransmitters [52], including acet-ylcholine (Ach) as seen in the nVH model [23, 28]. Visinin-like protein 1 [53] and neurocalcin d [54] are known to bind toclathrin-coated vesicles, well established to be involved inneurotransmitter release. Their observed reduced expres-sion, as well as that of clathrin light chain B, could henceaffect the release of several neurotransmitters, includingglutamate. Neurotransmitter abnormalities are key featuresin schizophrenia, and hypoglutamatergia has been shown tooccur in the PFC of nVH lesioned rats [28] and possibly inschizophrenic patients [55].
4.2 Proteins involved in feedback mechanisms
Besides their role in transmitter release, STXb1, visinin-like1 and neurocalcin d, also play various roles in feedback
mechanisms. For example, at resting potential, STXb1 andits binding partner syntaxin form part of the SNARE com-plex and interact with the M2 muscarinic ACh autoreceptor(M2 mAChR), while at higher cellular polarization, dissocia-tion occurs [56, 57]. ACh binding to the M2 mAChR pro-motes SNARE complex-M2 mAChR interaction. Therefore,its down regulation in the PFC of nVH lesioned rats couldalter feedback inhibition mechanisms of ACh release [23,24].
4.3 Receptor expression and signaling
In several neurotransmitter systems, the vesicular endocy-tosis of receptors in response to their stimulation is neces-sary for downstream activation of transcription factors [58–60]. Receptor internalization as well as recruitment of recep-tors from intracellular pools to the surface require SNARE-dependent and clathrin-mediated trafficking. Because of therole of STXb1 in SNARE-dependent transport, and theimplication of clathrin light chain B, visinin-like protein 1[61, 62] and neurocalcin d [54] in clathrin-mediated traffick-ing, it is likely that the reduced expression of these proteins,as observed in the present study, could interfere with inter-nalization, signaling and/or surface expression of variousneurotransmitter receptors, including various dopaminergic
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
3576 F. G. G. Vercauteren et al. Proteomics 2007, 7, 3569–3579
Figure 4. Western blotting experiments (filledbars) confirmed the significant changes (Stu-dent’s t-test; p,0.05) in intensity of differentialproteins in PD60 nVH lesioned group comparedto sham-operated controls as observed in 2-DEanalysis (white bars). The average value ofintensity (volume6OD) of each 2-DE proteinspot and corresponding Western blotting bandcontaining samples obtained from the shamcontrol animals was established as reference,and average fold changes in intensity of corre-sponding spots/bands from the nVH lesionedrats are shown (expressed in percentage). Per-centage change of intensity observed inlesioned animals versus sham animals (L/S) isindicated below the graph (STXb1: syntaxin-binding protein 1b; PEBP: phosphatidylethanolamine-binding protein; ncald: neuro-calcin d; CLCB: clathrin light chain b; DLAT:dihydrolipoyl-lysine S-acetyl-transferase E2;VILIP-1: visinin-like protein 1).
Figure 5. Predominant subcellular distribution of the identifiedproteins (A) as indicated in the Swiss-Prot database, and theirdistribution in functional categories (B). Numbers of proteins arepresented in the graphs as percent of total for the various cate-gories.
[63], glutamatergic (mGluR1,5 [64–67], NMDA receptors [68,69]), cholinergic [54, 59–62], serotonergic [70] and certainpeptide receptors, for example, neuropeptide Y receptors Y1and Y5 [71, 72].
4.4 Modulation of neurotransmission
In our study, a down regulation of PEBP, pyruvate dehy-drogenase, CKB and ATP synthase b was detected in PD60nVH lesioned rats. These proteins play an important role incholinergic neurotransmission, including choline acetyl-transferase (ChAT) activity, development of cholinergic neu-rons, signal transduction from the plasma membrane tocytoplasm [73, 74] and cholinergic receptor function [75, 76].The decreased levels of this set of proteins could thus con-tribute to the altered cholinergic neurotransmission knownto occur in adult nVH lesioned animals [25]. This is of inter-est considering evidence for aberrant cholinergic respon-siveness in schizophrenia [77]. Moreover, CKB and pyruvatedehydrogenase are well known to be involved in the main-tenance of normal GABAergic neurotransmission [78, 79],and CKB plays a role in normal dopaminergic signaling [80].Changes in expression of these proteins could thus interferewith GABAergic and dopaminergic signal transduction.
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2007, 7, 3569–3579 Animal Proteomics 3577Ta
ble
1.Li
sto
fid
enti
fied
pro
tein
sw
ith
sig
nif
ican
tly
alte
red
exp
ress
ion
inth
eP
FCo
fPD
60n
VH
lesi
on
edra
ts
SSP
Obs
Mr
(kDa
)Th
eor
Mr
(Da)
Obs
pITh
eor
pIN
o.AA
Prot
ein
nam
eAc
cess
ion
num
ber
Entry
nam
e%
Seq.
cov.
MAS
COT
scor
eN
o.of
pept
.L
vs.
sham
Upor
dow
n(%
)
p (t-te
st)
Gene
nam
eCh
rom
oso
me
Subc
ellu
larl
ocat
ion
(Sw
iss-
Prot
)
309
7067
568
76.
559
4Sy
ntax
in-b
indi
ngpr
otei
n1b
P617
65ST
XB1_
RAT
2276
15Do
wn
340.
021
Stxb
p1;
Unc1
8a9q
34.1
Plas
ma
mem
bran
e,sy
napt
icve
sicl
es,c
ytop
lasm
486
5645
192
5.7
5.48
400
mKI
AA10
45pr
otei
nQ9
UPV7
K104
5_HU
MAN
3121
316
Dow
n26
0.02
5KI
AA10
459p
13.3
Unkn
own
608
4842
712
5.4
5.33
381
Crea
tine-
kina
seB
P073
35KC
RB_R
AT31
136
12Do
wn
230.
012
Ckbb
14q3
2Pl
asm
am
embr
ane,
cyto
plas
m10
0724
2067
04.
95.
4818
6PE
BPP3
1044
PEBP
_RAT
3375
6Do
wn
410.
013
PEBP
2p36
.21
Plas
ma
mem
bran
e,cy
topl
asm
1042
2122
114
4.7
5.23
192
Neu
roca
lcind
P616
01N
CALD
_HUM
AN40
839
Dow
n39
0.00
4N
CALD
8q22
.2Pl
asm
am
embr
ane
1050
2022
011
4.5
5.01
190
Visi
nin-
like
prot
ein
1P6
2762
VISL
1_RA
T40
779
Dow
n34
0.03
1Vi
sl1
2p24
.3Pl
asm
am
embr
ane,
clat
hrin
coat
edve
sicl
es,G
olgi
1425
5456
354
4.6
5.18
529
ATP
synt
hase
bP1
0719
ATPB
_RAT
3618
815
Up24
0.00
8At
p5b
12p1
3Pl
asm
am
embr
ane,
mito
chon
dria
1436
4025
117
3.7
4.56
229
Clat
hrin
light
chai
nb
P080
82CL
CB_R
AT26
121
8Do
wn
620.
004
CLTB
4q2-
q3Pl
asm
am
embr
ane,
clat
hrin
coat
edpi
ts,c
lath
rinco
ated
vesi
cles
1432
6958
764
5.6
5.7
555
Dihy
drol
ipoy
l-lys
ine
S-ac
etyl
-tran
s-fe
rase
E2
P084
61OD
P2_R
AT2
672
Up36
0.02
4Dl
at11
q23.
1M
itoch
ondr
ia
PE
BP,
ph
osp
hat
idyl
eth
ano
lam
ine
bin
din
gp
rote
in.S
po
tnu
mb
er(S
SP
),o
bse
rved
and
theo
reti
calm
ole
cula
rw
eig
ht(
Mr)
and
pI,
nu
mb
ero
fam
ino
acid
s(A
A)a
nd
Sw
iss-
Pro
tacc
essi
on
nu
mb
eran
den
try
nam
ear
ein
dic
ated
.MA
SC
OT
resu
lts
fore
ach
pro
tein
are
rep
rese
nte
das
per
cen
tag
eo
fseq
uen
ceco
vera
ge
(%se
q.c
ov.
),M
AS
CO
Tsc
ore
and
nu
mb
ero
fpep
tid
es(n
o.
ofp
ept.
).T
he
chan
ge
and
leve
lofc
han
ge
oft
he
resp
ecti
vep
rote
ins,
asw
ella
sp-
valu
e,d
eter
min
edu
sin
gS
tud
ent’s
t-tes
t(p,
0.05
),ar
ein
dic
ated
.Fin
ally
,co
rres
po
nd
ing
gen
en
ame
asw
ella
sch
rom
oso
me
loca
tio
nan
dce
llula
rlo
cati
on
asin
dic
ated
inth
eS
wis
s-P
rotd
atab
ase
for
each
oft
hes
ep
rote
ins
are
liste
d.
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
3578 F. G. G. Vercauteren et al. Proteomics 2007, 7, 3569–3579
Finally, CKB as well as pyruvate dehydrogenase play impor-tant roles in energy metabolism. Their down regulationcould be in accordance with hypofrontality observed inschizophrenic patients [81]. Hence, changed levels of theseproteins could have broad consequences in our model as wellas in schizophrenia.
In summary, the present study demonstrated modifica-tions in the level of a number of neurotransmission-relatedproteins at the level of the plasma membrane and synapticvesicles in the PFC of PD60 nVH lesioned rats, a neurode-velopmental model that has been shown to display schizo-phrenia-like behaviors. The proteins identified in this studymay hence contribute to generate a global picture of alteredprotein expression at the level of exocytosis and endocytosisin the different neurotransmitter systems that have beenobserved to be changed in the nVH lesioned model, and mayfurther clarify the molecular mechanisms that are altered inthis animal model. The applied protein solubilization andorganelle proteomic approach allowed a quantitative com-parison of 392 spots on highly reproducible, high-resolution2-DE proteomic patterns of brain protein fractions enrichedin plasma membranes and vesicles. This method enabled theidentification of several altered neurotransmission-relatedproteins, including proteins of low abundance. Furtherstudies using this method should allow for the developmentof detailed proteomic maps of the nVH model of schizo-phrenia, focusing, for example, on different time-pointspostlesion and different brain regions, or following drugtreatments, and providing novel insights as to key pathwaysand proteins involved in schizophrenia.
This work was supported by grants from the Canadian Insti-tutes of Health Research (CIHR) to R. Q. and L. K. S. and agrant of the Research Council of the KULeuven (OT 05/33). TheR�seau Prot�omique de Montr�al-Montreal Proteomics Network(RPMPN) initiative, McGill University, is financially supportedby an operating grant from Genome Qu�bec. G. F. is a member ofthe Researcher National System of Mexico. The authors aregrateful to Professor Dr. Karl-Heinz Braunewell (HumboldtUniversity, Berlin, Germany) for his generous gift of the anti-visinin-like protein 1 antibody.
5 References
[1] van Os, J., Epidemiol. Psychiatr. Soc. 2003, 12, 242–252.
[2] Kasper, S., Tauscher, J., Kufferle, B., Barnas, C. et al., Eur.Arch. Psychiatry Clin. Neurosci. 1999, 249, 83–89.
[3] Miyamoto, S., Duncan, G. E., Marx, C. E., Lieberman, J. A.,Mol. Psychiatry 2005, 10, 79–104.
[4] Weinberger, D. R., Clin. Ther. 2005, 27, S8–S15.
[5] Shifman, S., Bronstein, M., Sternfeld, M., Pisante-Shalom, A.et al., Am. J. Hum. Genet. 2002, 71, 1296–1302.
[6] Fujii, Y., Shibata, H., Kikuta, R., Makino, C. et al., Psychiatr.Genet. 2003, 13, 71–76.
[7] Addington, A. M., Gornick, M., Duckworth, J., Sporn, A. etal., Mol. Psychiatry 2005, 10, 581–588.
[8] Chen, M. L., Chen, S. Y., Huang, C. H., Chen, C. H., Mol. Psy-chiatry 2002, 7, 447–448
[9] Norton, N., Moskvina, V., Morris, D. W., Bray, N. J. et al., Am.J. Med. Genet. B Neuropsychiatr. Genet. 2005, 141, 96–101.
[10] Chowdari, K. V., Mirnics, K., Semwal, P., Wood, J. et al., Hum.Mol. Genet. 2002, 11, 1373–1380.
[11] Millar, J. K., Christie, S., Anderson, S., Lawson, D. et al., Mol.Psychiatry 2001, 6, 173–178.
[12] Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjorns-dottir, S. et al., Am. J. Hum. Genet. 2002, 71, 877–892.
[13] Straub, R. E., Jiang, Y., MacLean, C. J., Ma, Y. et al., Am. J.Hum. Genet. 2002, 71, 337–348.
[14] Karson, C. N., Mrak, R. E., Schluterman, K. O., Sturner, W. Q.et al., Mol. Psychiatry 1999, 4, 39–45.
[15] Clinton, S. M., Haroutunian, V., Meador-Woodruff, J. H., J.Neurochem. 2006, 98, 1114–1125.
[16] Harrison, P. J., Curr. Opin. Neurobiol. 1997, 7, 285–289.
[17] Harrison, P. J., Weinberger, D. R., Mol. Psychiatry 2005, 10,40–68.
[18] Singh, S. M., McDonald, P., Murphy, B., O’Reilly, R., Clin.Genet. 2004, 65, 435–440.
[19] Lipska, B. K., Jaskiw, G. E., Weinberger, D. R., Neuropsycho-pharmacology 1993, 9, 67–75.
[20] Flores, G., Barbeau, D., Quirion, R., Srivastava, L.K., J. Neu-rosci. 1996, 16, 2020–2026.
[21] Marcotte, E. R., Pearson, D. M., Srivastava, L. K., J. Psy-chiatry Neurosci. 2001, 26, 395–410.
[22] Lipska, B. K., J. Psychiatry Neurosci. 2004, 29, 282–286.
[23] Laplante, F., Srivastava, L. K., Quirion, R., J. Neurochem.2004, 89, 314–323.
[24] Laplante, F., Stevenson, C. W., Gratton, A., Srivastava, L. K.,Quirion, R., J. Neurochem. 2004, 91, 1473–1482.
[25] Laplante, F., Nakagawasai, O., Srivastava, L. K., Quirion, R.,Neuropsychopharmacology 2005, 30, 1076–1087.
[26] Sams-Dodd, F., Lipska, B. K., Weinberger, D. R., Psycho-pharmacology (Berl.) 1997, 132, 303–310.
[27] Chambers, R. A., Moore, J., McEvoy, J. P., Levin, E. D. Neu-ropsychopharmacology 1996, 15, 587–594.
[28] Schroeder, H., Grecksch, G., Becker, A., Bogerts, B., Hoellt,V., Psychopharmacology (Berl.) 1999, 145, 61–66.
[29] Lipska, B. K., Lerman, D. N., Khaing, Z. Z., Weinberger, D. R.,Eur. J. Neurosci. 2003, 18, 3097–3104.
[30] Flores, G., Alquicer, G., Silva-Gomez, A. B. et al., Neu-roscience 2005, 133, 463–470.
[31] Kozarova, A., Petrinac, S., Ali, A., Hudson, J. W., J. ProteomeRes. 2006, 5, 1051–1059.
[32] Wang, S., Cheng, Q., Methods Mol. Biol. 2006, 316, 49–65.
[33] Lubec, G., Krapfenbauer, K., Fountoulakis, M., Prog. Neuro-biol. 2003, 69, 193–211.
[34] Vercauteren, F. G., Bergeron, J. J., Vandesande, F., Arckens,L., Quirion, R., Eur. J. Pharmacol. 2004, 500, 385–398.
[35] Vercauteren, F. G. G., Clerens, S., Roy, L., Hamel, N. et al.,Mol. Brain Res. 2004, 132, 241–259.
[36] Brunet, S., Thibault, P., Gagnon, E., Kearney, P. et al., TrendsCell Biol. 2003, 13, 629–638.
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2007, 7, 3569–3579 Animal Proteomics 3579
[37] Yates, J. R., III, Gilchrist, A., Howell, K. E., Bergeron, J. J.,Nat. Rev. Mol. Cell Biol. 2005, 6, 702–714.
[38] Kislinger, T., Cox, B., Kannan, A., Chung, C. et al., Cell 2006,125, 173–186.
[39] Foster, L. J., de Hoog, C. L., Zhang, Y., Zhang, Y. et al., Cell2006, 125, 187–199.
[40] Wilkins, M. R., Gasteiger, E., Sanchez, J.-C., Bairoch, A.,Hochstrasser, D. F., Electrophoresis 1998, 19, 1501–1505.
[41] Santoni, V., Molloy, M., Rabilloud, T., Electrophoresis 2000a,21, 1054–1070.
[42] Santoni, V., Kieffer, S., Desclaux, D., Masson, F., Rabilloud,T., Electrophoresis 2000b, 21, 3329–3344.
[43] Paxinos, G., Watson, C. The Rat Brain Atlas in StereotaxicCoordinates. 4th Edn., Academic Press, New York 1998.
[44] Chevallet, M., Santoni, V., Poinas, A., Rouquie, D. et al.,Electrophoresis 1998, 19, 1901–1909.
[45] Rabilloud, T., Blisnick, T., Heller, M., Luche, S. et al., Electro-phoresis 1999, 20, 3603–3610.
[46] Luche, S., Santoni, V., Rabilloud, T., Proteomics 2003, 3, 249–253.
[47] Yang, B., Steegmaier, M., Gonzalez, L. C., Scheller, R. H., J.Cell Biol. 2000, 148, 247–252.
[48] Misura, K. M. S., Scheller, R. H., Weis, W. I., Nature 2000, 404,355–362.
[49] Dulubova, I., Sugita, S., Hill, S., Hosaka, M. et al., EMBO J.1999, 18, 4372–4382.
[50] Mitchell, S. J., Ryan, T. A., Neuropharmacology 2005, 48,372–380.
[51] Graham, M. E., Barclay, J. W., Burgoyne, R. D., J. Biol. Chem.2004, 279, 32751–32760.
[52] Schutz, D., Zilly, F., Lang, T., Jahn, R., Bruns, D., Eur. J. Neu-rochem. 2005, 21, 2419–2432.
[53] Brackmann, M., Schuchmann, S., Anand, R., Braunewell, K.H., J. Cell Sci. 2005, 118, 2495–2505.
[54] Ivings, L., Pennington, S. R., Jenkins, R., Weiss, J. L., Bur-goyne, R. D., Biochem. J. 2002, 363, 599–608.
[55] Tamminga, C., Br. J. Psychiatry 1999, 37, 12–15.
[56] Ilouz, N., Branski, L., Parnis, J., Parnas, H., Linial, M., J. Biol.Chem. 1999, 274, 29519–29528.
[57] Linial, M., Ilouz, N., Parnas, H., J. Physiol. 1997, 504, 251–258.
[58] Liu, Z., Tearle, A. W., Nai, Q., Berg, D. K., J. Neurosci. 2005,25, 1159–1168.
[59] van Koppen, C. J., Biochem. Soc. Trans. 2001, 29, 505–508.
[60] Popova, J. S., Rasenick, M. M., J. Biol. Chem. 2004, 279,30410–30418.
[61] Braunewell, K. H., Brackmann, M., Schaupp, M., Spilker, C.et al., J. Neurochem. 2001, 78, 1277–1286.
[62] Lin, L., Jeanclos, E. M., Treuil, M., Braunewell, K. H. et al., J.Biol. Chem. 2002, 277, 41872–41878.
[63] Kim, K. M., Valenzano, K. J., Robinson, S. R., Yao, W. D. et al.,J. Biol. Chem. 2001, 276, 37409–37414.
[64] Mundell, S. J., Matharu, A. L., Pula, G., Holman, D. et al.,Mol. Pharmacol. 2002, 61, 1114–1123.
[65] Luis Albasanz, J., Fernandez, M., Martin, M., Brain Res. Mol.Brain Res. 2002, 99, 54–66.
[66] Petralia, R. S., Wang, Y. X., Wenthold, R. J., Eur. J. Neurosci.2003, 18, 3207–3217.
[67] Pula, G., Mundell, S. J., Roberts, P. J., Kelly, E., J. Neu-rochem. 2004, 89, 1009–1020.
[68] Nong, Y., Huang, Y. Q., Ju, W., Kalia, L. V. et al., Nature 2003,422, 302–307.
[69] Nakamichi, N., Yoneda, Y., J. Pharmacol. Sci. 2005, 97, 348–350.
[70] Roth, B. L., Willins, D. L., Kristiansen, K., Kroeze, W. K.,Pharmacol. Ther. 1998, 79, 231–257.
[71] Parker, S. L., Parker, M. S., Lundell, I., Balasubramaniam, A.et al., Regul. Pept. 2002, 107, 49–62.
[72] Pheng, L. H., Dumont, Y., Fournier, A., Chabot, J. G. et al., Br.J. Pharmacol. 2003, 139, 695–704.
[73] Ojika, K., Mitake, S., Tohdoh, N., Appel, S. H. et al., Prog.Neurobiol. 2000, 60, 37–83.
[74] Jope, R. S., Jenden, D. J., J. Neurochem. 1980, 35, 318–325.
[75] Wallimann, T., Waltzthony, D., Wegmann, G., Moser, H. et al.,J. Cell. Biol. 1985, 100, 1063–1072.
[76] Hu, D., Cao, K., Peterson-Wakeman, R., Wang, R., Biochem.Biophys. Res. Commun. 2002, 297, 729–736.
[77] Hyde, T. M., Crook, J. M., J. Chem. Neuroanat. 2001, 22, 53–63.
[78] Andres, R. H., Ducray, A. D., Huber, A. W., Perez-Bouza, A. etal., J. Neurochem. 2005, 95, 33–45.
[79] Waagepetersen, H. S., Sonnewald, U., Schousboe, A., Neu-roscientist 2003, 9, 398–403.
[80] Andres, R. H., Huber, A. W., Schlattner, U., Perez-Bouza, A. etal., Neuroscience 2005, 133, 701–713.
[81] Andreasen, N. C., O’Leary, D. S., Flaum, M., Nopoulos, P. etal., Lancet 1997, 349, 1730–1734.
ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com